Results 181 to 190 of about 447,250 (290)

Protocol-Specific Luteinizing Hormone Thresholds for IVF Pregnancy Outcomes: The Moderating Role of Age in a Retrospective Study of 217 Cycles. [PDF]

Int J Womens Health
Zhao J, Guan H, Wang M, Tang L, Tang H.
europepmc   +1 more source

Investigation Into the Metabolism and Elimination Behavior of RU 58841, and Its Influence on the Steroid Profile in Humans

Biomedical Chromatography, Volume 40, Issue 10, October 2026.
ABSTRACT RU 58841 is a nonsteroidal antiandrogen, developed for the treatment of androgen‐dependent conditions. This study aimed to characterize the human metabolism of RU 58841 for the first time and to assess its systemic exposure following topical administration.
Aylin Okutan, Oliver Krug, Gregor Fußhöller, Thomas Piper, Mario Thevis   +4 more
wiley   +1 more source

Basal Luteinizing Hormone Combined with Age and BMI as a Simplified Screening Model for Central Precocious Puberty in Girls. [PDF]

Int J Womens Health
Li J, Cui Y, Shuai J, Li W, Li Y, Yan Z, Yu T.   +6 more
europepmc   +1 more source

Oocyte–cumulus cell interaction: a key factor in early embryo development

Biological Reviews, Volume 101, Issue 5, Page 2265-2278, October 2026.
ABSTRACT The evaluation of oocyte competence is a fundamental step in achieving successful outcomes following assisted reproduction techniques (ART). At present, however, conventional oocyte maturation assessment is carried out by morphological observation, which is a subjective method that does not consider molecular features.
Marc Torres‐Garrido, Marc Yeste, Yentel Mateo‐Otero   +2 more
wiley   +1 more source

Estrogenic prevention of luteinizing hormone releasing hormone agonist-induced bone loss. [PDF]

J Endocrinol
Wells KV, Goodson ML, Lim KE, Robling AG, Genetos DC.   +4 more
europepmc   +1 more source

Diagnostic Discordance in Recurrent Pregnancy Loss: Hysteroscopy Resolves Ultrasound–MRI Disagreement in Septate Uterus, but Concurrent Ovulation Induction Precludes Causal Attribution of the Reproductive Outcome

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Congenital uterine anomalies are an important and potentially treatable contributor to recurrent pregnancy loss (RPL). The septate uterus is the commonest Müllerian anomaly linked to first‐trimester loss, and its differentiation from the benign arcuate uterus is essential for management, yet imaging modalities may disagree.
Iftekhar Ahmed Sakib, Ayesa Perveen, Nishad Tasnim   +2 more
wiley   +1 more source

The role of luteinizing hormone in the management of female infertility: A French Delphi consensus. [PDF]

J Assist Reprod Genet
Cédrin-Durnerin I, Labrosse J, Bridoux CC, de Buyst V, Paillet S, Lubrano M, Cerceau T, Bouée S, Salle B, Olivennes F, Jacquesson L.   +10 more
europepmc   +1 more source

The Effect of N‐Acetyl Cysteine on Serum Lipid Profile and Heavy Metals in Women With Endometriosis Undergoing ICSI: A Randomized Controlled Trial

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aims Endometriosis is associated with oxidative stress and heavy metal accumulation. This study evaluated whether N‐acetylcysteine (NAC) reduces serum heavy metals and improves lipid profiles in women with endometriosis undergoing fertility treatment.
Fatemeh Khorasani, Parvaneh Mirabi, Sedighe Esmaeilzadeh   +2 more
wiley   +1 more source

Comparison of Beiyi^® and its reference product Enantone^® as agonists of luteinizing hormone-releasing hormone against prostate cancer: a multicenter, randomized single-dose study. [PDF]

Front Pharmacol
Yi Y, Shen P, Zheng T, Hou R, Fan L, Yu Y, Li J, Fang Y, Hao C, You P, Lu X, Lu X, Wei Q, Feng P.   +13 more
europepmc   +1 more source

Preclinical and Toxicology Studies of LPM7100328, a Novel Oral GnRH Antagonist

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT LPM7100328 is a novel oral GnRH antagonist being developed for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation. The studies presented herein reported assessment of safety in favor of human clinical trials.
Yao Wang, Junxian Zhao, Fangxia Zou, Wanglin Jiang, Jianzhao Zhang, Pengfei Yu, Liang Ye, Xiaolin Sun, Chunmei Li, Jingwei Tian   +9 more
wiley   +1 more source